Does the media favor NTRA or BMRN?

In the previous week, Natera had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 36 mentions for Natera and 31 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Natera's score of 0.58 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 15 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BioMarin Pharmaceutical 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or BMRN?

In the previous week, BioMarin Pharmaceutical had 10 more articles in the media than Revolution Medicines. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 21 mentions for Revolution Medicines. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Revolution Medicines' score of 0.29 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 9 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral BioMarin Pharmaceutical 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BIIB or BMRN?

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Biogen. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 14 mentions for Biogen. Biogen's average media sentiment score of 0.80 beat BioMarin Pharmaceutical's score of 0.67 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 6 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BMRN or ALNY?

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 24 mentions for Alnylam Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Alnylam Pharmaceuticals' score of 0.04 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BMRN or INSM?

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than Insmed. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 24 mentions for Insmed. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Insmed's score of 0.62 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 7 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

BioMarin Pharmaceutical (BMRN) Competitors

$68.88 +5.07 (+7.95%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$68.93 +0.05 (+0.07%)

As of 04:09 AM Eastern

Compare

BMRN vs. NTRA, RVMD, BIIB, ALNY, and INSM

Should you buy BioMarin Pharmaceutical stock or one of its competitors? BioMarin Pharmaceutical's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioMarin Pharmaceutical compare to Natera?

Natera (NASDAQ:NTRA) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Natera has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Natera presently has a consensus target price of $301.90, indicating a potential downside of 5.17%. BioMarin Pharmaceutical has a consensus target price of $88.00, indicating a potential upside of 27.76%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71

BioMarin Pharmaceutical has a net margin of 2.14% compared to Natera's net margin of -7.11%. BioMarin Pharmaceutical's return on equity of 5.32% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.82%	-8.19%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

99.9% of Natera shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Natera had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 36 mentions for Natera and 31 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Natera's score of 0.58 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	15 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	19.77	-$208.16M	-$1.36	N/A
BioMarin Pharmaceutical	$3.22B	4.14	$348.90M	$0.37	186.16

Summary

BioMarin Pharmaceutical beats Natera on 9 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

In the previous week, BioMarin Pharmaceutical had 10 more articles in the media than Revolution Medicines. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 21 mentions for Revolution Medicines. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Revolution Medicines' score of 0.29 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	9 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BioMarin Pharmaceutical has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,830.91	-$1.13B	-$8.82	N/A
BioMarin Pharmaceutical	$3.22B	4.14	$348.90M	$0.37	186.16

Revolution Medicines has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Revolution Medicines currently has a consensus price target of $160.68, indicating a potential downside of 22.36%. BioMarin Pharmaceutical has a consensus price target of $88.00, indicating a potential upside of 27.76%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71

BioMarin Pharmaceutical has a net margin of 2.14% compared to Revolution Medicines' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Summary

BioMarin Pharmaceutical beats Revolution Medicines on 11 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Biogen?

Biogen (NASDAQ:BIIB) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.05	$1.29B	$5.65	36.66
BioMarin Pharmaceutical	$3.22B	4.14	$348.90M	$0.37	186.16

Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Biogen has a net margin of 8.32% compared to BioMarin Pharmaceutical's net margin of 2.14%. Biogen's return on equity of 11.18% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Biogen. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 14 mentions for Biogen. Biogen's average media sentiment score of 0.80 beat BioMarin Pharmaceutical's score of 0.67 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	6 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen presently has a consensus price target of $224.61, suggesting a potential upside of 8.44%. BioMarin Pharmaceutical has a consensus price target of $88.00, suggesting a potential upside of 27.76%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Biogen and BioMarin Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

BioMarin Pharmaceutical currently has a consensus target price of $88.00, suggesting a potential upside of 27.76%. Alnylam Pharmaceuticals has a consensus target price of $396.72, suggesting a potential upside of 82.84%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 24 mentions for Alnylam Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Alnylam Pharmaceuticals' score of 0.04 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.14	$348.90M	$0.37	186.16
Alnylam Pharmaceuticals	$4.80B	6.04	$313.75M	$5.38	40.33

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to BioMarin Pharmaceutical's net margin of 2.14%. Alnylam Pharmaceuticals' return on equity of 84.93% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Summary

Alnylam Pharmaceuticals beats BioMarin Pharmaceutical on 12 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Insmed?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

BioMarin Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.14	$348.90M	$0.37	186.16
Insmed	$606.42M	48.53	-$1.28B	-$4.11	N/A

BioMarin Pharmaceutical currently has a consensus target price of $88.00, indicating a potential upside of 27.76%. Insmed has a consensus target price of $205.52, indicating a potential upside of 52.52%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

BioMarin Pharmaceutical has a net margin of 2.14% compared to Insmed's net margin of -76.94%. BioMarin Pharmaceutical's return on equity of 5.32% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Insmed	-76.94%	-123.94%	-44.30%

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than Insmed. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 24 mentions for Insmed. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Insmed's score of 0.62 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	7 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Summary

BioMarin Pharmaceutical beats Insmed on 10 of the 17 factors compared between the two stocks.

Get BioMarin Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRN vs. The Competition

Export

Metric	BioMarin Pharmaceutical	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.35B	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.07%
P/E Ratio	186.16	9.09	269.20	24.72
Price / Sales	4.14	1,255.38	588.82	98.22
Price / Cash	22.36	44.95	28.89	37.42
Price / Book	2.17	17.66	11.27	6.42
Net Income	$348.90M	-$13.25M	$3.45B	$347.03M
7 Day Performance	13.44%	3.11%	1.92%	0.69%
1 Month Performance	16.51%	-1.68%	-0.58%	-0.90%
1 Year Performance	21.27%	61.75%	75.49%	21.87%

BioMarin Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRN BioMarin Pharmaceutical	4.5159 of 5 stars	$68.88 +7.9%	$88.00 +27.8%	+20.1%	$12.35B	$3.22B	186.16	3,221	Earnings Report Analyst Upgrade High Trading Volume
NTRA Natera	2.9105 of 5 stars	$315.98 +19.1%	$273.11 -13.6%	+109.5%	$45.24B	$2.50B	N/A	6,140	Earnings Report Analyst Forecast
RVMD Revolution Medicines	1.5572 of 5 stars	$197.13 -0.3%	$153.05 -22.4%	+491.3%	$41.97B	$11.58M	N/A	250	Earnings Report Analyst Forecast
BIIB Biogen	3.8869 of 5 stars	$206.26 0.0%	$224.61 +8.9%	+58.5%	$30.48B	$9.89B	36.51	7,500
ALNY Alnylam Pharmaceuticals	4.7165 of 5 stars	$215.25 -0.4%	$396.72 +84.3%	-50.6%	$28.78B	$3.71B	39.98	2,770

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRN) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does BioMarin Pharmaceutical compare to Natera?

Summary

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Summary

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Summary

How does BioMarin Pharmaceutical compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does BioMarin Pharmaceutical compare to Natera?

Which has more risk and volatility, NTRA or BMRN?

Do analysts rate NTRA or BMRN?

Is NTRA or BMRN more profitable?

Do insiders and institutionals believe in NTRA or BMRN?

Does the media favor NTRA or BMRN?

Which has preferable valuation and earnings, NTRA or BMRN?

Summary

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Does the media favor RVMD or BMRN?

Do insiders & institutionals believe in RVMD or BMRN?

Which has stronger earnings and valuation, RVMD or BMRN?

Which has more risk and volatility, RVMD or BMRN?

Do analysts prefer RVMD or BMRN?

Is RVMD or BMRN more profitable?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Which has better earnings and valuation, BIIB or BMRN?

Which has more risk & volatility, BIIB or BMRN?

Do insiders and institutionals have more ownership in BIIB or BMRN?

Is BIIB or BMRN more profitable?

Does the media favor BIIB or BMRN?

Do analysts prefer BIIB or BMRN?

Summary

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Do analysts rate BMRN or ALNY?

Which has more volatility & risk, BMRN or ALNY?

Does the media prefer BMRN or ALNY?

Which has better earnings and valuation, BMRN or ALNY?

Do insiders & institutionals have more ownership in BMRN or ALNY?

Is BMRN or ALNY more profitable?

Summary

How does BioMarin Pharmaceutical compare to Insmed?

Which has stronger valuation and earnings, BMRN or INSM?

Do analysts rate BMRN or INSM?

Is BMRN or INSM more profitable?

Do insiders and institutionals believe in BMRN or INSM?

Does the media refer more to BMRN or INSM?

Which has more volatility and risk, BMRN or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools